Antiphospholipid Syndrome Collaborative Registry (APSCORE)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Antiphospholipid Syndrome (APS) is an autoimmune disorder in which the body recognizes certain normal components of blood and/or cell membranes as foreign substances and produces antibodies against them. Patients with these antibodies may experience miscarriages and blood clotting disorders, including heart attacks and strokes. APS may occur in people with systemic lupus erythematosus and other autoimmune diseases, or in otherwise healthy individuals.
The Antiphospholipid Syndrome Collaborative Registry (APSCORE) is a national registry and tissue repository for patients with APS. This registry will collect clinical information and blood samples from people with APS.
| Condition |
|---|
|
Antiphospholipid Syndrome |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Antiphospholipid Syndrome Collaborative Registry (APSCORE) |
Serum, plasma, genomic DNA
| Enrollment: | 860 |
| Study Start Date: | April 2000 |
| Study Completion Date: | April 2007 |
| Primary Completion Date: | April 2007 (Final data collection date for primary outcome measure) |
Registry participants will have a blood sample drawn and will be interviewed about their medical histories. Participants will be asked to return for a follow-up visit after two years. Clinical, demographic, and laboratory data will be collected. Registry resources will be made available to researchers and medical practitioners to support a broad range of research on the causes, diagnosis, mechanisms, and treatment of APS.
The University of North Carolina at Chapel Hill is the coordinating center and an enrollment site for the registry. There are seven other enrollment sites: Ball Memorial Hospital, Muncie, IN; Duke University, Durham, NC; Hospital for Special Surgery, New York, NY; Johns Hopkins University, Baltimore, MD; Morehouse School of Medicine, Atlanta, GA; University of Texas Health Science Center, San Antonio, TX; and University of Utah Health Science Center, Salt Lake City, UT.
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Specialty and subspecialty clinics
Inclusion Criteria:
- Antiphospholipid antibodies with or without associated clinical manifestations
Contacts and Locations| United States, Georgia | |
| Morehouse School of Medicine | |
| Atlanta, Georgia, United States, 30310 | |
| United States, Maryland | |
| Johns Hopkins University | |
| Baltimore, Maryland, United States, 21205 | |
| United States, New York | |
| Hospital for Special Surgery, Weill-Cornell University Medical Center | |
| New York, New York, United States, 10021 | |
| United States, North Carolina | |
| University of North Carolina at Chapel Hill | |
| Chapel Hill, North Carolina, United States, 27599 | |
| Duke University Medical Center | |
| Durham, North Carolina, United States, 27710 | |
| United States, Texas | |
| University of Texas Health Science Center | |
| San Antonio, Texas, United States, 78229 | |
| United States, Utah | |
| University of Utah Health Science Center | |
| Salt Lake City, Utah, United States, 84132 | |
More Information
Additional Information:
Publications:
| Responsible Party: | Robert Roubey, MD, Associate Professor, University of North Carolina, Chapel Hill |
| ClinicalTrials.gov Identifier: | NCT00076713 History of Changes |
| Other Study ID Numbers: | NIAMS-099, N01AR002248-000 |
| Study First Received: | February 2, 2004 |
| Last Updated: | February 11, 2013 |
| Health Authority: | United States: Federal Government |
Keywords provided by University of North Carolina, Chapel Hill:
|
Antiphospholipid |
Additional relevant MeSH terms:
|
Antiphospholipid Syndrome Autoimmune Diseases Immune System Diseases |
ClinicalTrials.gov processed this record on May 23, 2013